Minding Couple (Compound Grendienone Tablets), a short-acting oral contraceptive with a lower dose of hormone content developed by Wyeth, is an enterprise dedicated to scientific research and product production and sales in the field of women's health care

Minulet is a short-acting contraceptive pill produced by Wyeth in the United States. The hormonal component of the sensitizer inhibits ovulation of the ovaries by inhibiting the release of gonadotropins, followed by changing the nature of the cervical mucus (making it difficult for sperm to penetrate) and changing the phase of the endometrium (making the possibility of fertilized egg implantation reduced), thus achieving contraception. Mindingeven is very similar to the progesterone secreted by the woman herself, and can achieve a hormonal balance that is close to the body's nature, so in addition to low dose and high efficiency, Mindingeven has almost no other possible side effects of traditional oral contraceptives, and also has the following beneficial drug effects: reduce the incidence of benign breast diseases; reduce the occurrence of iron deficiency anemia; Reduce the incidence of endometrial cancer, ectopic pregnancy, pelvic infection, ovarian cysts, dysmenorrhea; Reduces the severity of acne; It may also reduce the incidence of ovarian cancer. Pregnancy can be considered after the use of sensitizer is discontinued, and there is no need to wait another 6 months.

Wyeth has a long history of leadership in pharmaceuticals, vaccines and biotechnology. Wyeth has industry-leading products in the areas of women's health care, neurological diseases, musculoskeletal diseases, cardiovascular disease treatment, vaccines, anti-infection, hemophilia, immunology and anti-tumor products. Wyeth is also a leader in the field of nutraceuticals and health medicines.

On October 16, 2009, pharmaceutical giant Pfizer Inc. said it had completed a $68 billion deal to acquire Wyeth.